case_images: PMC10194834_01
case_images: Schematic diagram showing the treatment record of the patient.
case_images: fmed-10-1051034-g001.jpg
case_images: PMC10194834_01_fmed-10-1051034-g001.jpg
case_images: fig1
case_images: The patient was diagnosed with advanced Colon adenocarcinoma located in the right hepatic flexure hemicolon by pathological diagnosis (Figure 1.1). The treatment records are shown in Figure 1.
case_images: Serum tumor biomarker during treatment.
case_images: fmed-10-1051034-g002.jpg
case_images: PMC10194834_01_fmed-10-1051034-g002.jpg
case_images: fig2
case_images: After one cycle of treatment, the patient showed a significant quick reduction in CEA (from 104.3 to 5.28 ng/ml) and CA199 (from 59.32 to 17.63 ng/ml), indicative of response to the combination regime (Figure 2). After four cycles of treatment, the primary tumor mass reduced in size, the enlarged lymph nodes gradually shrank, and the CEA and CA199 returned to normal values, with a clinical evaluation of partial remission (PR) (Figures 2, 3A-F).
case_images: CT scans illustrating the changes in primary lesions and metastatic lymph nodes over time. (A) Primary lesion at the hepatic flexure (red arrow). (B) Supraclavicular lymph node (red arrow). (C) Tsubaortic lymph node (red arrow). (D) Paraesophageal lymph node (red arrow). (E) Retrotracheal lymph node (red arrow). (F) Subcarinal lymph node (red arrow).
case_images: fmed-10-1051034-g003.jpg
case_images: PMC10194834_01_fmed-10-1051034-g003.jpg
case_images: fig3
case_images: After four cycles of treatment, the primary tumor mass reduced in size, the enlarged lymph nodes gradually shrank, and the CEA and CA199 returned to normal values, with a clinical evaluation of partial remission (PR) (Figures 2, 3A-F). In May 2022, a PET-CT scan showed that the primary tumor disappeared (Figures 3A-F).